Company profile: NeoGenomics
1.1 - Company Overview
Company description
- Provider of cancer testing and partnership programs for pathologists and oncologists, offering diagnostic services (flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers), anatomic pathology (histology, tissue staining, digital pathology), NGS panels including Neo Comprehensive™ – Heme Cancers, Early-stage NSCLC Panel, InVisionFirst®-Lung, and pharma services for biomarker discovery, clinical trials, and companion diagnostics.
Products and services
- Diagnostic Services: Delivers NGS-integrated cancer testing, including flow cytometry, FISH, cytogenetics, and next-generation sequencing for solid tumors and hematologic cancers to support diagnosis and treatment planning
- Pharma Services: Supplies companion diagnostic-focused therapeutic development support for pharmaceutical partners, including biomarker discovery, clinical trial testing, and companion diagnostic development
- Neo Comprehensive™ – Heme Cancers: Produces DNA/RNA-based next-generation sequencing comprehensive testing menu for hematologic cancers to support precision oncology
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NeoGenomics
EsoBiotec
HQ: Belgium
Website
- Description: Provider of biotechnology solutions focused on the discovery of novel cancer therapies, aiming to enable the human body to fight cancer through in vivo cell engineering.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EsoBiotec company profile →
Acrivon Therapeutics
HQ: United States
Website
- Description: Provider of precision oncology therapeutics and companion diagnostics, leveraging the AP3 platform to develop drugs and OncoSignature tests that match therapies to tumor-driving mechanisms. Pipeline includes ACR-368, a phase 2 DNA damage response kinase inhibitor for solid cancers, and ACR-2316, a preclinical selective dual WEE1/PKMYT1 inhibitor.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acrivon Therapeutics company profile →
Formula Pharmaceuticals
HQ: United States
Website
- Description: Provider of oncology-focused CAR immunotherapies leveraging an allogeneic source, non-viral transfection, and a differentiated immune effector cell, plus diagnostic tests and research reagents including camelid nanobodies, a canine heartworm/tick-borne disease test, a SARS-CoV-2 antigen test, phosphate assay kits, leukocyte isolation solutions, and SDS-PAGE buffers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Formula Pharmaceuticals company profile →
Izotropic
HQ: United States
Website
- Description: Provider of breast CT imaging solutions, offering a high-resolution, 3D Breast CT Imaging System that captures approximately 500 images in a 10-second scan without compression; a robotic-guided Breast CT Biopsy System for imaging and sampling suspicious lesions and tumors for pathology testing; and Breast CT–based breast density measurement using 3D images and algorithms to estimate glandular volumes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Izotropic company profile →
SciBase
HQ: Sweden
Website
- Description: Provider of medical devices leveraging Electrical Impedance Spectroscopy (EIS) to detect malignant melanoma and assess skin barrier function. Products include Nevisense, a point-of-care platform using EIS and AI for non-invasive melanoma detection and objective clinical decision-making, and Nevisense Go, a portable EIS device for detailed skin barrier assessment in research.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SciBase company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NeoGenomics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NeoGenomics
2.2 - Growth funds investing in similar companies to NeoGenomics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NeoGenomics
4.2 - Public trading comparable groups for NeoGenomics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →